Logo

BD Fiscal Q1 Revenues Rise 10 Percent, R&D Surges 185 Percent, Profit Slides 35 Percent

Jan 25, 2007
NEW YORK (GenomeWeb News) — Becton Dickinson today said fiscal first-quarter 2007 revenues increased 8 percent as R&D spending surged 185 percent and profit dropped 35 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $1.5 billion from $1.4 billion year over year.
 
BD said revenues from its Diagnostics segment increased 2 percent to $442 million, while Biosciences revenue increased 11 percent to $232 million. Revenue from the Medical segment climbed 10 percent to $826 million.    
 
R&D spending for the quarter increased to $195 million from $68.3 million year over year. Contributing to the increase was a $115-million charge related to the completion of its acquisition of TriPath Imaging.
 
Net profits for the quarter slid to $142.9 million from $217.9 million in the year-ago period.
 
The company did not disclose its cash holdings.

Breaking News
The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.